Tag:
Valneva
Latest Headlines
Latest Headlines
Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII
Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be "highly immunogenic" while also offering a good safety and tolerability profile.
Valneva licenses EB66 technology to develop human, veterinary vaccines
Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.
Valneva picks up J&J;'s cholera vaccine--and some forthcoming competition
Johnson & Johnson's Crucell is officially out of the cholera space, and France's Valneva is in. And that means it's Valneva that's about to inherit some hefty competition that's coming up through its rivals' pipelines.
European scientists join Sanofi, Pfizer in C. diff vaccine race
With Sanofi having already begun enrollment for its 15,000-person Phase III trial, the French company has a clear lead in the race to develop a Clostridium difficile vaccine, but a growing pack is in pursuit. The latest to give chase is a group of European scientists with a new angle--they are developing an oral vaccine.
